Literature DB >> 2491962

Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.

R C Leonard1, G E Smart, J R Livingstone, M A Cornbleet, G R Kerr, S Fletcher, J N Webb, J F Smyth.   

Abstract

A total of 76 patients with advanced epithelial ovarian carcinoma were randomised to receive 6 months of treatment with either a combination of hexamethylmelamine, 5-fluorouracil, cisplatin and prednimustine or prednimustine alone following initial surgery. Pathologically confirmed response rates were 35% for combination chemotherapy and 28% for prednimustine, and the overall survival was identical for the two groups. Seven patients achieved a pathologically defined complete response, one of whom relapsed at 8 months; the others remain disease-free 18-36 months (median, 23 months) after presentation. The extent of initial surgery significantly affected the survival of patients receiving prednimustine but not of those receiving combination chemotherapy. Prednimustine can produce durable responses in advanced ovarian cancer using a schedule that results in negligible toxicity.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2491962     DOI： 10.1007/bf00273526

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  12 in total

1.  Studies on the toxicity and antitumour activity of prednimustine, a prednisolone ester of chlorambucil.

Authors:  K R Harrap; P G Riches; E D Gilby; S M Sellwood; R Wilkinson; I Konyves
Journal:  Eur J Cancer       Date:  1977-08       Impact factor: 9.162

2.  Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).

Authors:  J Carmo-Pereira; F O Costa; E Henriques; J A Ricardo
Journal:  Cancer       Date:  1981-11-01       Impact factor: 6.860

Review 3.  Chemotherapy of ovarian cancer.

Authors:  R F Ozols; R C Young
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

4.  Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma.

Authors:  J E Johnsson; C Tropé; W Mattsson; H Grundsell; K Aspegren; I Könyves
Journal:  Cancer Treat Rep       Date:  1979-03

5.  Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.

Authors:  J P Neijt; W W ten Bokkel Huinink; M E van der Burg; A T van Oosterom; R Vriesendorp; C D Kooyman; A C van Lindert; J V Hamerlynck; M van Lent; J C van Houwelingen
Journal:  Lancet       Date:  1984-09-15       Impact factor: 79.321

6.  Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line.

Authors:  B Hartley-Asp; P O Gunnarsson; J Liljekvist
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Prognosis of surgically determined complete responders in advanced ovarian cancer.

Authors:  D M Gershenson; L J Copeland; J T Wharton; E N Atkinson; N Sneige; C L Edwards; F N Rutledge
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

8.  A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer.

Authors:  J Løber; H T Mouridsen; I E Christiansen; P Dombernowsky; W Mattsson; M Rørth
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

9.  Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone.

Authors:  K Ideström; E Kimby; M Björkholm; H Mellstedt; L Engstedt; G Gahrton; B Johansson; D Killander; K H Robérts; A M Stalfelt; A M Udén; B Wadman; S Wählby
Journal:  Eur J Cancer Clin Oncol       Date:  1982-11

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640
View more
  3 in total

1.  Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

Authors: 
Journal:  BMJ       Date:  1991-10-12

2.  Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

Authors:  K Aabo; M Adams; P Adnitt; D S Alberts; A Athanazziou; V Barley; D R Bell; U Bianchi; G Bolis; M F Brady; H S Brodovsky; H Bruckner; M Buyse; R Canetta; V Chylak; C J Cohen; N Colombo; P F Conte; D Crowther; J H Edmonson; C Gennatas; E Gilbey; M Gore; D Guthrie; B Y Yeap
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

3.  Dose intensity analysis in advanced ovarian cancer patients.

Authors:  V Torri; E L Korn; R Simon
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.